Mankind Pharma has partnered with Denovo Sciences to enhance drug discovery through AI technology, signaling a significant advancement in their commitment to innovation in research and development.
This collaboration combines Mankind Pharma’s robust research and development capabilities with Denovo Sciences’ AI-driven molecular generation platform. The partnership employs a human-in-the-loop model, where AI assists in generating and evaluating molecular candidates, while scientific experts provide oversight and validation throughout the process. The primary objectives are to shorten drug discovery timelines, improve the quality of lead candidates, and ensure that only the most promising molecules progress to further development.
Sanjay Koul, President of R&D at Mankind Pharma, emphasized the importance of AI in accelerating early-stage discovery efforts, aiming to deliver better and more accessible therapies to patients. Hovakim Zakaryan, CEO of Denovo Sciences, highlighted the platform’s design to work in tandem with traditional drug discovery teams, ensuring that the integration of computational capabilities is complemented by expert insights.
The overarching aim of this partnership is to expedite the development of effective therapies for patients. This initiative reflects a growing trend in the pharmaceutical industry, where AI and machine learning are becoming integral to traditional discovery processes, thereby unlocking new avenues in tackling complex diseases.